SHANGHAI, CHINA -- (Marketwired) -- 07/08/13 -- Elsevier Business Intelligence and The BayHelix Group announce keynote speakers and program highlights for the fourth annual PharmAsia Summit (www.PharmAsiaSummit.com), scheduled for Oct. 21-23 in Shanghai.
The 2013 PharmAsia Summit will focus on new R&D and commercial models for a rapidly changing China biopharmaceutical market. From the government's push for innovation to increased pricing pressure on off-patent medications to faster growth in China's second-tier markets, the biopharmaceutical market in China is undergoing fundamental changes that require new business models and new ways of thinking.
"Given demographic changes and China's massive health care reforms and strong government support, opportunities abound for pharmaceutical and biotech companies, but so do potential pitfalls," said Jimmy Zhang, PhD, MBA, chairman of BayHelix and a member of the PharmAsia Summit organizing committee.
The Summit begins with the release of the 2nd annual PharmAsia Summit Report: "New Growth Models for China - Driving Growth In An Environment Of Intensifying Cost Pressure And A Push For innovation." McKinsey & Co., the knowledge partner for the 2013 PharmAsia Summit, will present the report with Elsevier Business Intelligence and BayHelix. The report's findings, based on an industry survey and interviews with key thought leaders, provide a framework for Summit attendees to better understand the changing dynamics of the China market.
"We believe the theme is of high relevance to all pharma MNCs given recent market-access developments, increasing government support for innovation, increasing number of business development deals between multinational and domestic pharmaceutical and biotech companies and the huge untapped potential of the market," said Franck Le Deu, leader of McKinsey's Greater China Healthcare Practice.
This year's Summit also features speakers from leading multinational and domestic pharmaceutical companies discussing new models to sustain growth via case studies, panels, and keynote talks. "Our agenda focuses on real-world examples from leading companies that are rising to the challenge of a changing pharmaceutical market in China," said Joshua Berlin, head of the emerging markets group at Elsevier Business Intelligence and a member of the PharmAsia Summit organizing committee.
Featured participants include:
•Ming Zhang, PhD, Head of R&D China, Amgen •David Snow, President, China and Hong Kong, AstraZeneca •Jean-Christophe Pointeau, President, Bristol-Myers Squibb China •Eric Zwisler, President, Cardinal Health China •Liangshang Zhang, PhD, President of Global R&D, Jiangsu Hengrui Medicine •Thad Huston, President, Xian Janssen Pharmaceutical Ltd., Johnson & Johnson •Franck Le Deu, Leader of Greater China Healthcare Practice, McKinsey & Company •Sophie Kornowski-Bonnet, Head of Partnering, Roche Pharmaceuticals •Luke Miels, Regional Head, Asia Pacific, Roche Pharmaceuticals •Jean-Luc Lowinski, PhD, Senior Vice President Asia Region, Sanofi •Henry Sun, PhD, CEO, Tasly Pharmaceuticals
The program for this year's Summit has been created by an organizing committee chaired by Steve Yang, PhD, VP, Head of Asia and Emerging Markets iMed, AstraZeneca.
For further information, please visit: http://www.PharmAsiaSummit.com.
About Elsevier Business Intelligence:
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit: http://www.ElsevierBi.com.
About BayHelix Group:
BayHelix is an organization of leaders of Chinese heritage in the global life sciences and healthcare community. We aspire to shape the growth of the life sciences and healthcare industry around the Pacific Rim and beyond, foster and create business opportunities, supply and nurture the leaders for the community, and network and share information and experience. BayHelix is a non-profit organization and its membership is by-invitation-only. For more information, visit: http://www.bayhelix.org.
Elsevier Business Intelligence
Lychee Group, LLC
Most Popular Stories
- Criminal Investigation Opened Into James Foley's Death
- The Hip New Career? Farming
- McDonald's Names Another U.S. President
- Student Startup Develops Date-rape Detector
- Sahara Casino Rises Anew as SLS Las Vegas
- Is Diversity in the Eye of the Beholder?
- Chinese Coal Gas Boom Poses Climate Risks
- Job Market Shifts Complicate Yellen's Rate Decision
- U.S. Supporters of Islamic State Get Close Scrutiny
- Dems Losing Fear of Obamacare